Shah Maulik R, Ramsey William J
Saint Louis University Cancer Center, Saint Louis University, Saint Louis, MO 63110, USA.
Cell Immunol. 2003 Oct;225(2):113-21. doi: 10.1016/j.cellimm.2003.10.004.
We have shown that vaccination of animals with two distinct commonly used glioma cell lines, 9L and RT2, generated cross-reactive cellular anti-tumor immunity. Peripheral vaccination with either cell line 9L or RT2 resulted in MHC Class I restricted effector cells capable of in vitro cytolytic activity against both target 9L and RT2 cells but not the syngeneic F98 glioma cell line. In vitro cross-reactive cytolytic activity could be measured for as long as 6 months from the time of initial vaccination. Fractionation of splenic effector cells revealed the cytolytic activity to be CD8+ T-cell mediated but required CD4+ T-cells for effective antigen presentation. Anti-tumor immunity generated after vaccination with either 9L or RT2 was completely protective against subsequent subcutaneous inoculation of animals with either 9L or RT2 cells and resulted in prolonged survival in animals inoculated intracranially with either cell line. Our results suggest that despite the different methods used in their derivation, 9L and RT2 glioma cells share a common glioma antigen recognized by the cellular arm of the immune response.
我们已经证明，用两种不同的常用胶质瘤细胞系9L和RT2对动物进行疫苗接种可产生交叉反应性细胞抗肿瘤免疫。用9L或RT2细胞系进行外周疫苗接种可产生MHC I类限制性效应细胞，这些细胞能够在体外对9L和RT2靶细胞具有溶细胞活性，但对同基因F98胶质瘤细胞系则没有活性。从初次接种疫苗开始，体外交叉反应性溶细胞活性可持续检测长达6个月。脾效应细胞的分级分离显示溶细胞活性是由CD8 + T细胞介导的，但需要CD4 + T细胞进行有效的抗原呈递。用9L或RT2接种疫苗后产生的抗肿瘤免疫对随后用9L或RT2细胞皮下接种动物具有完全的保护作用，并导致用任何一种细胞系进行颅内接种的动物存活时间延长。我们的结果表明，尽管9L和RT2胶质瘤细胞系的来源方法不同，但它们共享一种被免疫反应的细胞部分识别的共同胶质瘤抗原。
